Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Dermatology · Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis

Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP): A Patient Guide

At a Glance

POIKTMP is an ultra-rare FAM111B-related condition affecting the skin, muscles and tendons, lungs, liver, and pancreas. Although there is no cure, lifelong monitoring and coordinated supportive care can identify organ problems early and help protect mobility, nutrition, and quality of life.

Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis—commonly known by the acronym POIKTMP—is an ultra-rare genetic condition that affects multiple systems in the body. At its core, the disease involves a mutation in the FAM111B gene, which alters how cells maintain themselves [1][2]. Because only a few dozen cases have been documented worldwide, receiving this diagnosis can feel like entering uncharted territory, but understanding the general pattern of the disease can help you prepare for the road ahead.

The condition typically features overlapping possibilities rather than a rigid timeline, with manifestations linked to the genetic variant. These early indicators often appear on the skin as poikiloderma, a mottled pattern of pigmentation and thinned skin, alongside thin or absent hair and a reduced ability to sweat. As you or your child grows, the condition often involves the musculoskeletal system. Many individuals experience progressive muscle weakness and a tightening of the tendons, particularly in the calves and ankles, which can significantly impact mobility and the way they walk [3][4].

While the skin and muscle symptoms are the most apparent, the most serious aspects of POIKTMP involve the internal organs, specifically the lungs, liver, and pancreas. The mechanisms linking the FAM111B gene to these different organ manifestations are still being researched, but patients may develop significant breathing difficulties, pulmonary fibrosis, or liver dysfunction. In some cases, the pancreas may not produce enough enzymes to digest food properly, which can interfere with a child’s growth and nutrition [5][6]. Because these internal changes may not be visible from the outside, proactive and lifelong monitoring is the most important tool available to patients and caregivers.

Although there is currently no cure for POIKTMP, a dedicated team of specialists can help manage symptoms and preserve your quality of life. This multidisciplinary approach—combining the expertise of dermatologists, pulmonologists, hepatologists, and physical therapists—is designed to catch internal changes early and provide supportive care for muscle and skin issues. While the diagnosis is life-changing, staying informed and maintaining an individualized schedule of medical surveillance empowers you to advocate for yourself or your child and navigate the complexities of this condition with confidence [7][8].

Common questions in this guide

What is POIKTMP, and what causes it?
POIKTMP is an ultra-rare inherited condition caused by a change in the FAM111B gene. It can affect the skin, hair and sweating, muscles and tendons, lungs, liver, and pancreas.
What symptoms can appear first in POIKTMP?
Early signs often include poikiloderma, a mottled pattern of skin color and thinning, along with thin or absent hair and reduced sweating. Muscle weakness and tightening of the tendons, especially around the calves and ankles, may develop as a child grows.
Which internal organs can POIKTMP affect?
POIKTMP may affect the lungs, liver, and pancreas. Lung involvement can cause breathing problems or pulmonary fibrosis, while liver dysfunction and reduced pancreatic enzymes can interfere with digestion, nutrition, and growth.
Is there a cure for POIKTMP?
There is currently no cure for POIKTMP. Supportive care from specialists can help manage skin and muscle problems, preserve mobility, and identify internal organ changes as early as possible.
How is long-term care for POIKTMP coordinated?
Care usually involves a multidisciplinary team that may include dermatology, pulmonary, liver, and physical therapy specialists. The team can establish a baseline for internal organ health and create an individualized schedule of lifelong monitoring for the patient.

Get notified when new evidence is published on Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Expanding the clinical spectrum of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis due to FAM111B mutations.

    Mercier S, Küry S, Salort-Campana E, et al.

    Orphanet journal of rare diseases 2015; (10()):135 doi:10.1186/s13023-015-0352-4.

    PMID: 26471370
  2. 2

    FAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human disease.

    Hoffmann S, Pentakota S, Mund A, et al.

    EMBO reports 2020; (21(10)):e50662 doi:10.15252/embr.202050662.

    PMID: 32776417
  3. 3

    Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia.

    Takimoto-Sato M, Miyauchi T, Suzuki M, et al.

    Frontiers in genetics 2022; (13()):870192 doi:10.3389/fgene.2022.870192.

    PMID: 35601499
  4. 4

    Mutations within the putative protease domain of the human FAM111B gene may predict disease severity and poor prognosis: A review of POIKTMP cases.

    Arowolo A, Rhoda C, Khumalo N

    Experimental dermatology 2022; (31(5)):648-654 doi:10.1111/exd.14537.

    PMID: 35122327
  5. 5

    Expanding phenotype of FAM111B-related disease focusing on liver involvement: Literature review, report of a case with end-stage liver disease and proposal for a new acronym.

    Macchiaiolo M, Panfili FM, Vecchio D, et al.

    American journal of medical genetics. Part A 2022; (188(10)):2920-2931 doi:10.1002/ajmg.a.62906.

    PMID: 35869874
  6. 6

    [Pulmonary fibrosis associated with hereditary fibrosing poikiloderma caused by FAM111B mutation: A case report].

    Sanchis-Borja M, Pastré J, Mercier S, et al.

    Revue des maladies respiratoires 2018; (35(9)):968-973 doi:10.1016/j.rmr.2018.09.002.

    PMID: 30341002
  7. 7

    Hereditary fibrosing poikiloderma (POIKTMP syndrome) report of a new mutation and review of the literature.

    Hoeger PH, Koehler LM, Reipschlaeger M, Mercier S

    Pediatric dermatology 2023; (40(1)):182-187 doi:10.1111/pde.15133.

    PMID: 36102338
  8. 8

    Case report: Discovery of a de novo FAM111B pathogenic variant in a patient with an APECED-like clinical phenotype.

    Ferré EMN, Yu Y, Oikonomou V, et al.

    Frontiers in immunology 2023; (14()):1133387 doi:10.3389/fimmu.2023.1133387.

    PMID: 36875114

This POIKTMP page is for informational purposes only and does not constitute medical advice. Your multidisciplinary care team should tailor monitoring and supportive care to your or your child’s needs.